SIR, The paper by W A Manschot and R van Strik (Br J Ophthalmol 1987; 71: 348-52) is of value as it stimulates thinking about the controversies in melanoma treatment, but it lacks important relevant data.
The concept of tumour doubling time of the authors is an oversimplification, as they assume that there is only one growth potential of all tumour cells involved, whereas in fact a tumour consists of a heterogeneous group of cells of different growth potential. ' The statement that the tumour death rate of all patients with melanomas in the <7 mm diameter group is nil is incorrect. One patient out of 42 patients of Thomas et They elaborate on the results of Gass,' who found a much higher metastatic death after cobalt-60 irradiation than after enucleation, but omit to mention that the statistical reappraisal Gass had made of his results led to the conclusion 'that after adjusting for both size and location, the treatments were almost significantly different using a likelihood ratio test. This leads to the conclusion that the issue of which treatment is better for the patient is still not settled. '1 The authors have failed to mention results of several other long-term studies with a follow-up period of more than four years as advocated by them. Augsburger et al. " in an observational study of 237 patients with posterior uveal melanomas, 74-7% of whom were followed-up for five years or longer, 140 having been treated with enucleation and 97 with cobalt plaque radiotherapy, found after statistical adjustment for intergroup differences in risk factors that the difference in effect of enucleation versus cobalt plaque therapy on survival time was not statistically significant.
After cobalt-60 plaque irradiation of 123 patients Hungerford (personal communication, 1987) found no difference statistically in metastatic death from the comparable group of patients treated by enucleation after an observation period of 10 to 20 years.
Lommatzsch ' evaluated the results of 188 patients with choroidal melanomas treated with Ru-106 applicators followed up for more than five years with a mean period of 9-4 years. Of this group 18 (9.6% ) had died from metastases. These results and the survival rate after irradiation of 79-5% (death only from metastases) after 10 years confirmed his earlier results'3 that the survival rate after local beta irradiation is higher than after enucleation of tumours of a comparable size. ' The results of the long-term studies may not allow definite proof that the rate of metastasis is lower after irradiation than after enucleation, but the data obtained until now at least provide the reassurance that the long-term studies do not show a superiority of enucleation over irradiation as regards survival rate. Therefore irradiation of a choroidal melanoma is medically justifiable and a recommended treatment for patients with choroidal melanomas. We feel that every patient has not only the right to enucleation but also to radiotherapy within the limits of the different types of irradiation. ' and, surprisingly, substantiate their criticism with a histopathological report which actually had been made by one of us (WAM). The specimen concerned a blind, painful eye, which had to be enucleated within four months after a ruthenium irradiation of a small uveal melanoma in the clinic of one of our critics (AW). The apparently excessive radiotherapy had caused severe necrosis of almost all intraocular tissue, including the melanoma. Oosterhuis etal. point specifically to the reported complete necrosis of the small melanoma, but they do not appear to be alarmed by the total loss of the eye.
Paragraph 5 (The authors state ...): Taking credit for a necrotic melanoma in a subtotally necrotic inner eye appears equivalent to taking credit for the finding 'that only in a few cases viable tumour cells could not be found' in enucleated irradiated eyes. The major part of 27 most recently reported4 histopathologically studied irradiated eyes had not been enucleated because of continuing or relapsing tumour growth but because of postirradiation damage. The passage on the carefully controlled' patients is a red herring. Tumour cells 'sterilised' by irradiation are, so far, an unsubstantiated fantasy for most of the irradiated patients. Moreover, ophthalmic pathologists are familiar with the fact that mitotic figures are also difficult to find in most non-irradiated melanomas. The 'information (which) has already been given by Char' on destruction by radiation of the tumour's integrity' is hypothetical, as appears from the only published mean 10-year follow-up report by Gass' (next paragraph).
Paragraph 6 (Concerning ... ): More favourable results of radiotherapy as compared with enucleation, concerning metastatic death, have never been reported by any author who has presented a >5-year follow-up survival statistic of all irradiated patients. Again Oosterhuis et al. neglected to substantiate this crucial remark. Gass' provided a mean 10-year follow-up survival rate for all 27 enucleated and 21 irradiated patients and revealed a 22% death rate after enucleation against 57% after irradiation, while the mean survival after enucleation was >10 years against 3-8 years after irradiation. These figures have not reached statistical significance as yet because of the small numbers of these patients; they are, however, highly impressive for the unbiased reader.
Paragraphs 7-9 with reference to reports of Lommatzsch and Gragoudas. We have not 'failed to mention results of several other long-term studies with a follow-up period of more than four years.. .' as Oosterhuis et al. state incorrectly. We have studied carefully the published reports, which were included in the bibliography. The papers by Augsburger et al. 7 Lommatzsch ,8 and Gragoudas et al.9 were published after our paper had been submitted. They cannot, therefore, be used in criticism of our paper. It is of interest that two of these papers present once again statistics on selected groups of patients instead of irradiated patients in toto. The third paper is based on a mean follow-up of 5-4 years. The readers will have noticed that our paper emphasises that after a 5-year follow-up some indications might be provided, but that 10-year or longer follow-up periods are needed to achieve decisive arguments. We have also stressed that tumour-related death after enucleation has appeared to decrease steadily to a low percentage in the second 5-year follow-up period. Tumour biology suggests, however, that after irradiation the remaining tumour tissue will either continue or restart its exponential growth. Then dissemination and death from metastases will tend to increase exponentially in the second 5-year follow-up period, as was shown by Gass. Irradiation of uveal melanomas is still based on hypotheses and on too short follow-up periods in selected subgroups of patients, by which considerable selection artefacts have been incurred. Patients with uveal melanoma have the right to be treated by enucleation, which eliminates any further dissemination. Radiotherapyof uveal melanomas is justified only in patients with a short life expectancy and in patients who refuse enucleation. In recent years he played a major part in developing the interests of ophthamology, not least in his support for the proposed college of ophthalmologists, and was a wise and sympathetic adviser to his colleagues. He always displayed great charm and had an astute and inquiring mind.
In addition to his medical interests Brian Harcourt was a magistrate and a keen gardener, ornithologist, and sailor. He recently obtained his navigator's certificate and had great pleasure in taking his family sailing during his last summer. Above all he was devoted to his family, who were most loving and supportive during his illness.
Brian will always be remembered as a dear friend and colleague, and his death at the height of his career will be a great loss to British ophthalmology.
He leaves a widow, Margaret, and two sons, one a medical student, and a daughter who is training to be an ophthalmologist.
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